CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 20, 2021—Bio-Rad Laboratories launched the Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only. The assays allow scientists to measure neutralizing antibodies against wild-type and significant variants of the SARS-CoV-2 virus.
The Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel is a ready-to-use, 96-well kit containing premixed magnetic capture beads, a detection ACE2 receptor, a standard and positive control, and buffers that measure levels of neutralizing antibodies and percentage inhibition of the ACE2 receptor binding the viral antigens coupled on the beads. The assay requires 15 μL of sample when running duplicates.
“As variants of interest and concern become the predominant forms of SARS-CoV-2 infecting populations, it’s critical to understand whether the antibodies, elicited by a prior COVID-19 infection or vaccination, are still able to neutralize the circulating virus variants,” Candice Cox, Bio-Rad immunoassays marketing manager, Life Science Group, said in a press release. “We are pleased to be able to add these neutralizing antibody assays to our offering of existing Bio-Plex Pro IgA, IgG, and IgM four-plex serology kits for COVID-19–related research in vaccine development and postmarket surveillance studies.”
The assays are compatible with RUO Bio-Rad platforms, including the Bio-Plex 200 and Bio-Plex 3D multiplex immunoassay systems, as well as all other RUO xMAP platforms.